to peak of cortex; TTPi, time to peak of interlobar artery; TTPm, time to peak of medulla; TTPs, time to peak of segmental artery; ΔRTm-c, change in RT between medulla and cortex; ΔTTPm-c, change in TTP between medulla and cortex.
Results:
In the CR group, rising time (RT) and time to peak (TTP) of medulla (RTm and TTPm, respectively) were significantly longer compared to those in the AR group.
The kidney volume was significantly decreased in the CR group but was increased in the AR group. In the derivation group, age, change in kidney volume, and TTPm were identified as independent predictors by multivariate analysis. Based on the multivariate analysis results and area under receiver operating characteristic (ROC) curves (AUROCs) of individual markers, we constructed a new index as follows: P = −5.424 + 0.074 × age −9.818 × kidney volume change + 0.115 × TTPm; New Index = e P /(1 + e P ). The new index discriminates CR from AR and had better AUROCs than any other parameters.
Conclusion:
In conclusion, the new index provides a new diagnosis model for CR.
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| INTRODUC TI ON
Conventional ultrasound in combination with color Doppler imaging is a common and protocol examination for patients after renal transplantation. However, conventional ultrasound in combination with Doppler imaging can diagnose renal artery stenosis and vein thrombosis, but it is not possible to display subtle microvascular tissue perfusion. Apart from immunological factors, one of the most important factors to ensure a stable allograft function is renal blood supply, which is mainly influenced by parenchymal blood perfusion. Over 90% of renal blood flow in the renal cortex is provided by small renal arterioles and capillaries. 1, 2 Therefore, conventional ultrasound is not able to provide accurate and more information for the evaluation of acute and chronic allograft dysfunctions.
Contrast-enhanced ultrasonography, which employs microbubble contrast agents and complementary harmonic pulse sequences to demonstrate parenchymal perfusion, can be a helpful problemsolving tool in several clinical scenarios, including kidney diseases. 3 The main ultrasound contrast agent approved in Europe is SonoVue (BR1, Bracco, Milan, Italy). Contrast-enhanced ultrasonography is safe and well-tolerated in patients without renal toxicity and crossallergy anaphylactic reaction. 3, 4 The application of CEUS in renal transplants highlights its versatility in immediate problem solving without recourse to other potentially nephrotoxic agents. In addition, CEUS can uniquely provide additional information not available from other modalities about the microcirculation. 5 In our previous prospective study, we discriminated AR from ATN in renal allografts using CEUS. After establishing a mathematic model, AR can also be distinguished from non-AR recipients at any time period after transplantation. 6 However, whether CEUS can diagnose renal allograft CR has not been reported. Up to 50% of all rejection episodes are subclinical and occur without changes in standard parameters, such as creatinine or blood urea nitrogen. 7, 8 CR, which is mainly mediated by antibodies against donor antigens, has been the major cause of long-term graft loss. Vasculopathy and disturbances in allograft perfusion occur in CR. 9, 10 Most of these vascular insults affect small parenchymal arteries and arterioles, which cannot be assessed by conventional Doppler ultrasound. Thus, it might be helpful to provide CR diagnostic evidence by evaluating renal allograft microperfusion.
In this study, patients who were suspected of allograft rejection with normal serum cyclosporine A and tacrolimus concentrations received renal allograft biopsy. We evaluated the application of CEUS in the assessment of different pathologic renal allograft dysfunction (AR and CR) and further established a novel and simple noninvasive model for predicting CR.
| MATERIAL S AND ME THODS

| Patients
A total of 66 renal transplant recipients in the derivation group were enrolled in this prospective study from January 2011 to December 2016. For the validation group, 38 recipients were enrolled from January 2017 to September 2017. The validation group underwent the same studies as the derivation group. All patients received living-related or deceased donor kidneys. Due to increased SCr either rapidly or slightly, all patients received renal allograft biopsy for pathological diagnosis. Before biopsy, all patients were admitted to our abdominal ultrasound unit for ultrasound examination. Patients with renal allograft artery stenosis, artery or venous thrombus, renal allograft urinary obstruction, perirenal hematoma, ATN, BK virus-associated nephropathy, tubulointerstitial nephritis, CNI toxicity, and thrombotic microangiopathy were excluded. This study protocol was approved by the Ethics Committee. Procedures in this study were in accordance with the Helsinki Declaration of 2000, with informed consent from the participants. (Figure 1 ). In this study, the segmental artery was chosen as the reference region, and the QOF ≥ 75% between the reference region and the analysis region was regarded as the permission of enrolling. We used two quantitative parameters, RT and TTP, for further analysis. The repeatability was good, as previously described. 6 
| Ultrasound examination and principle of contrast-enhanced ultrasonography
| Blood and pathological examinations
| Data management and statistical analysis
The results were expressed as the mean values ± SD or median (interquartile range). In the derivation group, one-way ANOVA tests or independent sample t tests were used to compare the markers among the groups. Significant variables from the univariate analysis (P < 0.05) were then subjected to multivariate analysis by forwarding logistic regression to identify independent factors associated with either end point. CR was considered as a positive result and AR as a negative result. A predictive index was constructed by modeling the values of the independent variables. The diagnostic values of parameters were assessed by calculating the AUROCs. The best cutoff points were selected from the ROC curve to identify the presence or absence of CR. For that purpose, we selected cutoff points with a 90% certainty for the presence and absence of CR, thus regarding 10% false-negative or false-positive results as clinically acceptable; we also selected an optimal cutoff point according to the best Youden index. The diagnostic accuracy was calculated using Sen, specificity, NPV and PPV, and likelihood ratios. Then, the index derived in the derivation group was tested in the validation group. All data were analyzed using SPSS 19.0 (SPSS Inc., Chicago, USA).
| RE SULTS
| Demographics and baseline characteristics
In the derivation group, the mean age of all 66 enrolled patients (53 males, 13 females) was 39.1 ± 12.1 years. All patients were administered triple immunosuppressants, including MMF, cyclosporine A or tacrolimus, SRL, and Pred. The mean time from renal transplantation was 51 months (duration of 1 week to 180 months). In the validation group, the mean age of all patients (28 males, 10 females) was 41.4 ± 9.9 years. Patients in the validation group also received a standard triple ISP. The mean time from renal transplantation was 61 months (duration of 3 weeks to 228 months). In the derivation group, 41 patients presented AR, and 25 patients presented CR with a biopsy-proven histologic examination. In the validation group, there were 22 patients with AR and 16 patients with CR. There were no significant differences between the AR and CR groups in terms of sex, weight, BMI, or ISP in either the derivation or validation groups. The demographics and baseline characteristics of each group are shown in 
| Comparison of renal function and CEUS parameters
The patients with CR demonstrated significantly higher SCr and lower eGFR compared to the AR group (Figure 2A,B) . No difference was F I G U R E 1 CEUS quantification measurement and TIC. A, The 4 regions of interest were demonstrated. Yellow circle: segmental artery; green circle: interlobar artery; purple dotted circle: medulla; purple solid circle: cortex. B, In AR and CR kidneys, the TIC was coarse, especially in the AR kidney, with apparent ups and downs. In addition, the peak of the TIC for CR was sharper than AR observed in RI between these two groups ( Figure 2C ). The kidney volume change was calculated as (volume 2-volume 1)/volume 1. The volume 2 was tested by B-mode ultrasound examination before CEUS was performed. The volume 1 was tested within 24 hours post-transplantation. In the CR group, the kidney volume change was significantly decreased compared to that in the AR group ( Figure 2D ). The RT and TTP of the medulla (RTm and TTPm) were significantly longer in the CR group than those in the AR group (Figure 2E ,F). 
| Predictors of CR and establishment of the diagnostic model
| Comparison of the new index with individual markers for predicting CR
Area under ROC curves were used to evaluate the overall diagnostic performance of this new index and individual markers ( Figure 3A ). We found that this new index had a better AUROC than that of kidney volume change, eGFR, and individual CEUS markers.
Additionally, this new index was superior to individual markers when optimal cutoff values were applied ( Table 5 ).
| Validation of the new index
The characteristics of patients in the validation group are summarized in Table 1 . No differences were observed in SCr, eGFR, and RI values between the AR and CR groups ( Figure 4A Figure 4G) . The AUROC is shown in Figure 3B (AUROC = 0.90, 95% CI 0.81-0.99, P < 0.001).
Upon applying a high cutoff value (New Index = 0.70), CR was predicted in 26% of patients with PPV 90%, and upon applying a low cutoff value (New Index = 0.36), CR was excluded with 86% certainty in 55% of patients (Table 4 ). Finally, the new index showed no significant differences between the TCMR and ABMR subgroups in CR patients ( Figure 4H ). Based on the results, we found that the essential difference be- a lower microperfusion speed, which means a higher resistance of renal artery and arteriole. Allograft rejection is a complex process that involves the interplay of different cellular and molecular pathways that cause a broad range of allograft injuries. Allograft rejection can be hyperacute (occurring within minutes after the vascular anastomosis), acute (occurring days to weeks after transplantation), late acute (occurring 3 months after transplantation), or chronic (occurring months to years after transplantation). The major pathological changes of AR were lymphocytic infiltration, interstitial edema, intimal arteritis, tubulitis and arteritis. 13, 14 However, CR is much more complex than AR. Currently, the main pathology of CR is ABMR. Despite the major advances in molecular biology and gene rearrangement, the diagnosis of ABMR is still dependent on histologic findings. 15 The typical pathology of chronic ABMR is vascular endothelium injury. 16 Therefore, CEUS, a quantitative method for evaluating microperfusion, is able to discriminate CR from AR. In addition, RT and TTP parameters in CR are significantly increased compared to those in the AR group. In addition to the CEUS parameter TTPm, kidney volume change is also an important parameter for the new index formula. In the AR and CR groups, the kidney volume presented absolutely different variation tendencies. Mechanically, the swelling of the renal pyramids that occurs in AR is caused by the intense reaction initiated by the immune response. Although CR is also mediated by immune rejection similar to AR, the immune response is weaker and slower.
| D ISCUSS I ON
Han et al analyzed 351 living-donor kidney transplantation patients.
They also found that the low-graft-volume group conferred a greater risk of rejection, chronic change, and graft loss than that in the highgraft-volume group. 18 In addition to CR, interstitial fibrosis and tubular atrophy (IF/TA) is another confounding factor in the late stage of renal transplantation. Therefore, IF/TA is indeed a very important factor that is worth considering. This factor is also a limitation of the current study and will be investigated in the future. Although the precise CEUS parameters that may best predict disease still warrant systematic evaluations, animal models, and limited clinical trials in humans, our study raises hopes that CEUS could outcompete other modalities as a firstline tool for assessing renal perfusion noninvasively. 19 However, due to the limited number of kidney transplantation cases, the validation group was rather small, and a power analysis was not performed.
Our results should be validated in further studies with large sample sizes, and the cutoff values may need to be adjusted or modified based on the results from further larger studies.
In our study, the new index cannot discriminate sub-phenotypes of CR, such as TCMR and ABMR. Although the major cause of CR is ABMR, the therapies for TCMR and ABMR are different.
ABMR is mediated by donor-specific antibodies generated by plasma cells. The common therapeutic strategy for ABMR is IVIG, plasmapheresis, antithymocyte globulin, or rituximab. However, steroid pulse therapy and increased immunosuppressants are usually applied for TCMR. Mechanically, TCMR is mediated by T cells, rather than B cells. Therefore, if CEUS could differentiate TCMR and ABMR, it will be helpful for doctors to makes decisions for treatments. It is inspiring that there are some preliminary animal studies using targeted CEUS. For instance, in a rat kidney transplant study, microbubble contrast agents were coupled with anti-CD3, anti-CD4, and anti-CD8 antibodies. Strikingly, CD3-mediated ultrasound, which suggests T-cell infiltration, allows the detection of AR as early as postoperative day 2. 20 Similarly, Sun et al detected C4d deposition in vivo in rat kidney and heart transplant models of ABMR using C4d-targeted microbubbles with a streptavidin-biotin conjugation. 21, 22 These studies further enhanced the specificity of CEUS in detecting allograft rejection and provide the potential for discriminating between ABMR and TCMR in the future.
In conclusion, CEUS is a reliable and useful tool for the diagnosis and follow-up after kidney transplantation, allows for the visualization of kidney allograft microperfusion in different circumstances and is an accurate, specific, and sensitive method for the assessment of CR. Moreover, the new index established in our study provides assistance in the diagnosis of CR with a high degree of accuracy and convenience.
PER S PEC TIVE
Contrast-enhanced ultrasonography (CEUS) is a noninvasive imaging tool for collecting quantitative measurements of regional renal perfusion and microvascular function. Here we established a model to diagnose renal allograft chronic rejection using CEUS. We believe that antibody-coupled CEUS which named as molecular ultrasound image will be more specific and attractive in the future. 
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